3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: A potential microbicide for preventing sexual transmission of HIV-1

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 1700-1711

  Li, Lin ^a,b   He, Lili ^a   Tan, Suiyi ^a,b   Guo, Xinhua ^b   Lu, Hong ^b   Qi, Zhi ^b   Pan, Chungen ^b   An, Xiuli ^b,c   Jiang, Shibo ^a,b   Liu, Shuwen ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b NEW YORK BLOOD CENTER   (United States)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYPHTHALIC ANHYDRIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ARGININE; CD4 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; LYSINE; MICROBICIDE; OVALBUMIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BIOTYPE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SEXUAL TRANSMISSION; VIRUS ENTRY; VIRUS ISOLATION;

ANIMALS; ANTI-HIV AGENTS; ARGININE; CHICKENS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; EPITHELIAL CELLS; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LYSINE; MEMBRANE FUSION; MOLECULAR WEIGHT; OVALBUMIN; PHTHALIC ANHYDRIDES; PROTEIN STRUCTURE, SECONDARY; SEXUALLY TRANSMITTED DISEASES, VIRAL; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 77951216905     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01046-09     Document Type: Article

References (78)

1. Boscolo, P., A. del Signore, E. Sabbioni, M. Di Gioacchino, L. Di Giampaolo, M. Reale, P. Conti, R. Paganelli, and M. Giaccio. 2003. Effects of resveratrol on lymphocyte proliferation and cytokine release. Ann. Clin. Lab. Sci. 33: 226-231.
2. Carballo-Dieguez, A., I. C. Balan, K. Morrow, R. Rosen, J. E. Mantell, F. Gai, S. Hoffman, L. Maslankowski, W. El-Sadr, and K. Mayer. 2007. Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a phase I clinical trial (HPTN 050). AIDS Care 19:1026-1031.
3. Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.
4. Check, E. 2007. Scientists rethink approach to HIV gels. Nature 446:12.
5. Chou, T. C., and M. P. Hayball. 1991. CalcuSyn: Windows software for dose effect analysis. Biosoft, Ferguson, MO.
6. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
7. Clavel, F., D. Guetard, F. Brun-Vezinet, S. Chamaret, M. A. Rey, M. O. Santos-Ferreira, A. G. Laurent, C. Dauguet, C. Katlama, C. Rouzioux, et al. 1986. Isolation of a new human retrovirus from West African patients with AIDS. Science 233:343-346.
8. Dezzutti, C. S., V. N. James, A. Ramos, S. T. Sullivan, A. Siddig, T. J. Bush, L. A. Grohskopf, L. Paxton, S. Subbarao, and C. E. Hart. 2004. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob. Agents Chemother. 48:3834-3844.
9. Eggink, D., C. E. Baldwin, Y. Deng, J. P. M. Langedijk, M. Lu, R. W. Sanders, and B. Berkhout. 2008. Selection of T1249-resistant human immunodeficiency virus type 1 variants. J. Virol. 82:6678-6688.
10. Elton, D., L. Medcalf, K. Bishop, D. Harrison, and P. Digard. 1999. Identification of amino acid residues of influenza virus nucleoprotein essential for RNA binding. J. Virol. 73:7357-7367.
11. Fichorova, R. N., F. Zhou, V. Ratnam, V. Atanassova, S. Jiang, N. Strick, and A. R. Neurath. 2005. Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation. Antimicrob. Agents Chemother. 49:323-335.
12. Fields, R. 1972. The rapid determination of amino groups with TNBS. Methods Enzymol. 25:464-469.
13. Gisselquist, D., and J. J. Potterat. 2003. Heterosexual transmission of HIV in Africa: an empiric estimate. Int. J. STD AIDS 14:162-173. (Pubitemid 36308017)
14. Gollub, E. L., and Z. Stein. 1992. Nonoxynol-9 and the reduction of HIV transmission in women. AIDS 6:599-601.
15. Gyotoku, T., L. Aurelian, and A. R. Neurath. 1999. Cellulose acetate phthalate (CAP): an 'inactive' pharmaceutical excipient with antiviral activity in the mouse model of genital herpesvirus infection. Antivir. Chem. Chemother. 10:327-332.
16. Harouse, J. M., A. Gettie, R. C. Tan, J. Blanchard, and C. Cheng-Mayer. 1999. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284:816-819.
17. Harouse, J. M., R. C. Tan, A. Gettie, P. Dailey, P. A. Marx, P. A. Luciw, and C. Cheng-Mayer. 1998. Mucosal transmission of pathogenic CXCR4-utilizing SHIVSF33A variants in rhesus macaques. Virology 248:95-107.
18. Harrison, C., and E. Chantler. 1998. The effect of nonoxynol-9 and chlorhexidine on HIV and sperm in vitro. Int. J. STD AIDS 9:92-97.
19. Hillier, S. L., T. Moench, R. Shattock, R. Black, P. Reichelderfer, and F. Veronese. 2005. In vitro and in vivo: the story of nonoxynol 9. J. Acquir. Immune Defic. Syndr. 39:1-8.
20. Hsu, M., J. M. Harouse, A. Gettie, C. Buckner, J. Blanchard, and C. Cheng-Mayer. 2003. Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. J. Virol. 77:989-998.
21. Huang, J. H., Z. Qi, F. Wu, L. Kotula, S. Jiang, and Y. H. Chen. 2008. Interaction of HIV-1 gp41 core with NPF motif in Epsin: implication in endocytosis of HIV. J. Biol. Chem. 283:14994-15002.
22. Huntington, J. A., and P. E. Stein. 2001. Structure and properties of ovalbumin. J. Chromatogr. B Biomed. Sci. Appl. 756:189-198.
23. Jespers, V. A., J. M. Van Roey, G. I. Beets, and A. M. Buve. 2007. Doseranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J. Acquir. Immune Defic. Syndr. 44:154-158.
24. Jiang, S., and A. K. Debnath. 2000. Development of HIV entry inhibitors targeted to the coiled coil regions of gp41. Biochem. Biophys. Res. Commun. 269:641-646.
25. Jiang, S., Y.-Y. Li, N. Strick, A. R. Neurath, K. S. George, C. Chuoudhury, and B. Esmaeli-Azad. 1997. Virucidal and antibacterial activities of 3-hydroxyphthaloyl β-lactoglobulin, p. 327-330. In R. M. Chanock, H. S. Ginsberg, F. Brown, and R. A. Lerner (ed.), Vaccines 97. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
26. Jiang, S., K. Lin, and M. Lu. 1998. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J. Virol. 72:10213-10217.
27. Jiang, S., K. Lin, and A. R. Neurath. 1991. Enhancement of human immunodeficiency virus type-1 (HIV-1) infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J. Exp. Med. 174:1557-1563.
28. Jiang, S., K. Lin, N. Strick, Y.-Y. Li, and A. R. Neurath. 1996. Chemically modified bovine β-lactoglobulin blocks uptake of HIV-1 by colon- and cervix-derived epithelial cells. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13:461-462.
29. Jiang, S., K. Lin, L. Zhang, and A. K. Debnath. 1999. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J. Virol. Methods 80:85-96.
30. Jiang, S., H. Lu, S. Liu, Q. Zhao, Y. He, and A. K. Debnath. 2004. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents Chemother. 48:4349-4359.
31. Joshi, S., S. Dutta, B. Bell, A. Profy, J. Kuruc, F. Gai, M. Cianciola, L. Soto-Torres, A. Panchanadikar, A. Risbud, S. Mehendale, and S. J. Reynolds. 2006. Phase I safety study of 0.5% PRO 2000 vaginal gel among HIV un-infected women in Pune, India. AIDS Res. Ther. 3:4.
32. Keller, M. J., and B. C. Herold. 2009. Understanding basic mechanisms and optimizing assays to evaluate the efficacy of vaginal microbicides. Sex. Transm. Dis. 36:S92-S95.
33. Kokuba, H., L. Aurelian, and A. R. Neurath. 1998. 3-Hydroxyphthaloyl beta-lactoglobulin. IV. Antiviral activity in the mouse model of genital herpesvirus infection. Antivir. Chem. Chemother. 9:353-357.
34. Lewis, E., B. Rogachev, G. Shaked, and A. Douvdevani. 2001. The in vitro effects of ketamine at large concentrations can be attributed to a nonspecific cytostatic effect. Anesth. Analg. 92:927-929.
35. Li, M., L. Li, S. Jiang, and J. Zhang. 2008. A non-infectious assay for detecting HIV-1 Env-induced cell-cell fusion. J. Jinan Univ. (Med. Sci.) 28:576-580. (In Chinese.)
36. Limpakarnjanarat, K., T. D. Mastro, S. Saisorn, W. Uthaivoravit, J. Kaewkungwal, S. Korattana, N. L. Young, S. A. Morse, D. S. Schmid, B. G. Weniger, and P. Nieburg. 1999. HIV-1 and other sexually transmitted infections in a cohort of female sex workers in Chiang Rai, Thailand. Sex. Transm. Infect. 75:30-35.
37. Liu, S., H. Lu, A. R. Neurath, and S. Jiang. 2005. Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. Antimicrob. Agents Chemother. 49:1830-1836.
38. Liu, S., Q. Zhao, and S. Jiang. 2003. Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: applicable for identification of the HIV-1 fusion inhibitors. Peptide 24:1303-1313.
39. Lu, H., Q. Zhao, G. Wallace, S. Liu, Y. He, R. Shattock, A. R. Neurath, and B. S. Jiang. 2006. Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. AIDS Res. Hum. Retroviruses 22:411-418.
40. Lu, L., Y. Zhu, J. Huang, X. Chen, H. Yang, S. Jiang, and Y. H. Chen. 2008. Surface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core. J. Biol. Chem. 283:16723-16731.
41. Lu, M., and P. S. Kim. 1997. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 15:465-471.
42. Mayer, K. H., S. A. Karim, C. Kelly, L. Maslankowski, H. Rees, A. T. Profy, J. Day, J. Welch, and Z. Rosenberg. 2003. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 17:321-329.
43. Mayer, K. H., L. A. Maslankowski, F. Gai, W. M. El-Sadr, J. Justman, A. Kwiecien, B. Masse, S. H. Eshleman, C. Hendrix, K. Morrow, J. F. Rooney, and L. Soto-Torres. 2006. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 20:543-551.
44. Miceli, M. C., and J. R. Parnes. 1993. Role of CD4 and CD8 in T cell activation and differentiation. Adv. Immunol. 53:59-122.
45. Miller, C. J., and J. Hu. 1999. T cell-tropic simian immunodeficiency virus (SIV) and simian-human immunodeficiency viruses are readily transmitted by vaginal inoculation of rhesus macaques, and Langerhans' cells of the female genital tract are infected with SIV. J. Infect. Dis. 179(Suppl. 3):S413-S417.
46. Neurath, A. R., A. K. Debnath, N. Strick, Y.-Y. Li, K. Lin, and S. Jiang. 1995. Blocking of CD4 cell receptors for the human immunodeficiency virus type 1 (HIV-1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis. J. Mol. Recognit. 8:304-316.
47. Neurath, A. R., A. K. Debnath, N. Strick, Y.-Y. Li, K. Lin, and S. Jiang. 1997. 3-Hydroxyphthaloyl-β-lactoglobulin. I. Optimization of production and comparison with other compounds considered for chemoprophylaxis of mucosally transmitted HIV. Antivir. Chem. Chemother. 8:53-61.
48. Neurath, A. R., A. K. Debnath, N. Strick, Y.-Y. Li, K. Lin, and S. Jiang. 1997. 3-Hydroxyphthaloyl-β-lactoglobulin. II. Anti-HIV-1 activity in vitro in environments relevant to prevention of sexual transmission of the virus. Antivir. Chem. Chemother. 8:141-148.
49. Neurath, A. R., S. Jiang, N. Strick, K. Lin, Y.-Y. Li, and A. K. Debnath. 1996. Bovine β-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptors for HIV-1. Nat. Med. 2:230-234.
50. Neurath, A. R., N. Strick, S. Jiang, Y. Y. Li, and A. K. Debnath. 2002. Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. BMC Infect. Dis. 2:6.
51. Neurath, A. R., N. Strick, and Y. Y. Li. 1998. 3-Hydroxyphthaloyl beta-lactoglobulin. III. Antiviral activity against herpesviruses. Antivir. Chem. Chemother. 9:177-184.
52. Neurath, A. R., N. Strick, and Y. Y. Li. 2002. Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides. BMC Infect. Dis. 2:27.
53. Neurath, A. R., N. Strick, Y. Y. Li, and A. K. Debnath. 2001. Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect. Dis. 1:17.
54. Nisbet, A. D., R. H. Saundry, A. J. Moir, L. A. Fothergill, and J. E. Fothergill. 1981. The complete amino-acid sequence of hen ovalbumin. Eur. J. Biochem. 115:335-345.
55. Olsen, J. V., S. E. Ong, and M. Mann. 2004. Trypsin cleaves exclusively C-terminal to arginine and lysine residues. Mol. Cell. Proteomics 3:608-614.
56. Palaparthy, R., H. Wang, and A. Gulati. 2000. Current aspects in pharmacology of modified hemoglobins. Adv. Drug Deliv. Rev. 40:185-198.
57. Parish, C. R., L. Low, H. S. Warren, and A. L. Cunningham. 1990. A polyanion binding site on the CD4 molecule. Proximity to the HIV-gp120 binding region. J. Immunol. 145:1188-1195.
58. Perotti, M. E., A. Pirovano, and D. M. Phillips. 2003. Carrageenan formulation prevents macrophage trafficking from vagina: implications for microbicide development. Biol. Reprod. 69:933-939.
59. Roehr, B. 2009. Microbicide offers no protection against HIV infection. BMJ 339:b5538.
60. Rusconi, S., M. Moonis, D. P. Merrill, P. V. Pallai, E. A. Neidhardt, S. K. Singh, K. J. Willis, M. S. Osburne, A. T. Profy, J. C. Jenson, and M. S. Hirsch. 1996. Naphthalene sulfonate polymers with CD4-blocking and antihuman immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. 40:234-236.
61. Schwartz, J. L., G. Kovalevsky, J. J. Lai, S. A. Ballagh, T. McCormick, K. Douville, C. K. Mauck, and M. M. Callahan. 2008. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. Sex. Transm. Dis. 35:414-419.
62. Schwartz, R. H. 2003. T cell anergy. Annu. Rev. Immunol. 21:305-334.
63. Shattock, R. J., and R. W. Doms. 2002. AIDS models: microbicides could learn from vaccines. Nat. Med. 8:425.
64. Shattock, R. J., and J. P. Moore. 2003. Inhibiting sexual transmission of HIV-1 infection. Nat. Rev. Microbiol. 1:25-34.
65. Skoler-Karpoff, S., G. Ramjee, K. Ahmed, L. Altini, M. G. Plagianos, B. Friedland, S. Govender, A. De Kock, N. Cassim, T. Palanee, G. Dozier, R. Maguire, and P. Lahteenmaki. 2008. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372:1977-1987.
66. Stone, A., and S. Jiang. 2006. Microbicides: stopping HIV at the gate. Lancet 368:431-433.
67. Tabet, S. R., M. M. Callahan, C. K. Mauck, F. Gai, A. S. Coletti, A. T. Profy, T. R. Moench, L. E. Soto-Torres, A. N. Poindexter III, R. G. Frezieres, T. L. Walsh, C. W. Kelly, B. A. Richardson, L. Van Damme, and C. L. Celum. 2003. Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J. Acquir. Immune Defic. Syndr. 33: 476-483.
68. Tao, W., C. Richards, and D. Hamer. 2008. Enhancement of HIV infection by cellulose sulfate. AIDS Res. Hum. Retroviruses 24:925-929.
69. Turpin, J. A. 2002. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin. Investig. Drugs 11:1077-1097.
70. UNAIDS. 2008. 2008 Report on the global AIDS epidemic. http://www.unaids .org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008-Global-report .asp.
71. Van Damme, L., V. Chandeying, G. Ramjee, H. Rees, P. Sirivongrangson, M. Laga, and J. Perriens. 2000. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group. AIDS 14:85-88.
72. Van Damme, L., G. Ramjee, M. Alary, B. Vuylsteke, V. Chandeying, H. Rees, P. Sirivongrangson, L. Mukenge-Tshibaka, V. Ettiegne-Traore, C. Uaheowitchai, S. S. Karim, B. Masse, J. Perriens, and M. Laga. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360:971-977.
73. Van Damme, L., R. Govinden, F. M. Mirembe, F. Guedou, S. Solomon, M. L. Becker, B. S. Pradeep, A. K. Krishnan, M. Alary, B. Pande, G. Ramjee, J. Deese, T. Crucitti, and D. Taylor. 2008. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359:463-472.
74. Van Herrewege, Y., J. Michiels, J. Van Roey, K. Fransen, L. Kestens, J. Balzarini, P. Lewi, G. Vanham, and P. Janssen. 2004. In vitro evaluation of non-nucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob. Agents Chemother. 48:337-339.
75. Wang, H., Z. Qi, A. Guo, Q. Mao, H. Lu, X. An, C. Xia, X. Li, A. K. Debnath, S. Wu, S. Liu, and S. Jiang. 2009. ADS-J1 inhibits HIV-1 entry by interacting with the gp41 pocket region and blocking the fusion-active gp41 core formation. Antimicrob. Agents Chemother. 53:4987-4998.
76. Xiong, W., Y. Zhao, A. Prall, T. C. Greiner, and B. T. Baxter. 2004. Key roles of CD4+ T cells and IFN-gamma in the development of abdominal aortic aneurysms in a murine model. J. Immunol. 172:2607-2612.
77. Yamasaki, R. B., A. Vega, and R. E. Feeney. 1980. Modification of available arginine residues in proteins by p-hydroxyphenylglyoxal. Anal. Biochem. 109:32-40.
78. Zhao, Q., J. T. Ernst, A. D. Hamilton, A. K. Debnath, and S. Jiang. 2002. XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res. Hum. Retroviruses 18:989-997.